Fans of Jaguar Health (NASDAQ:JAGX) stock will want to keep an eye on the company tomorrow as it prepares for an investor webcast.
Investors will want to tune into that webcast as it will cover topics relevant to the company. That includes going over the “unmet need associated with cancer therapy-related diarrhea (CTD).” Breast cancer oncologist Lee Schwartzberg will discuss the topic.
In addition to that, another topic of discussion will be Jaguar Health’s mental health Entheogen Therapeutics Initiative (ETI). This has the company planning to “discover novel, therapeutic opportunities derived from psychoactive plants.” Former National Geographic Explorer-in-Residence Wade Davis will cover this topic.
The investor webcast is set to take place at 10:30 a.m. Eastern on Jan. 12, 2023. Investors that want to check out the webcast can register and participate by following this link.
Other JAGX Stock News Today
Recently, Jaguar Health also announced that Sandra Swain has joined the Jaguar/Napo Scientific Advisory Board (SAB). One of the main focuses of Swain’s career is “addressing the gastrointestinal toxicities of cancer therapies.” That makes her joining relevant to the company’s webcast tomorrow.
JAGX stock is also seeing heavy trading volume with today’s news. As of this writing, more than 58 million shares have changed hands. That’s a massive surge over the daily average trading volume of about 4.5 million shares.
JAGX stock is rising 11.8% as of Wednesday afternoon.
Investors seeking out the latest stock market news will want to stick around!
We’ve got all of the hottest stock coverage that traders need to know about on Wednesday! That includes everything happening with shares of Biora Therapeutics (NASDAQ:BIOR), CarMax (NYSE:KMX) and Bionano Genomics (NASDAQ:BNGO) stock. You can read up on that at the links below!
More Wednesday Stock Market News
- Why Is Biora Therapeutics (BIOR) Stock Up 12% Today?
- KMX Stock Alert: What to Know as JPMorgan Downgrades CarMax
- Bionano Genomics (BNGO) Stock Pops on Promising Publication
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.